Therapeutic Action
Centrally acting antihypertensive
PDF page 211
Loading InternPractice…
Drug reference
Centrally acting antihypertensive
PDF page 211
Hypertension in pregnancy
PDF page 211
Do not administer to patients with active liver disease, history of drug-induced hepatitis, severe depression. Administer with caution to patients with hepatic impairment, and reduce doses in patients with renal impairment. May cause: orthostatic hypotension, drowsiness, headache, gastrointestinal disturbances, dry mouth; rarely: haematological, hepatic, mental disorders; allergic reactions. Stop treatment in the event of haemolytic anaemia or jaundice. In the event of unexplained fever during treatment, check blood count and transaminases for possible hepatitis due to methyldopa. Monitor combination with lithium (risk of lithium overdose), antidepressants (enhanced hypotensive effect), CNS depressants (increased sedation). Pregnancy: no contra-indication Breast-feeding: no contra-indication
PDF page 211
250 mg tablet
PDF page 211
Initially 250 mg 2 to 3 times daily for 2 days, then increase gradually if necessary by 250 mg every 2 to 3 days, until the optimal dose is reached, usually 1.5 g daily. Do not exceed 3 g daily.
PDF page 211
According to clinical response. Do not stop treatment abruptly; reduce doses gradually.
PDF page 211
Below 25 °C
PDF page 212